XBI241213C88500
- 0.00
- 0.000.00%
SPDR S&P Biotech ETF Newsroom
Exact Sciences Analyst Ratings
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Natera Analyst Ratings
Gilead Sciences Says Committee For Medicinal Products For Human Use Of European Medicines Agency Recommends Seladelpar For Treatment Of Primary Biliary Cholangitis In Combination With Ursodeoxycholic Acid (UDCA) In Adults With Inadequate Response To...
Vir Gets FDA Breakthrough Therapy Status for Two Drugs
SPDR S&P Biotech ETF Options Spot-On: On December 12th, 124.48K Contracts Were Traded, With 924.94K Open Interest
On December 12th ET, $SPDR S&P Biotech ETF(XBI.US)$ had active options trading, with a total trading volume of 124.48K options for the day, of which put options accounted for 69.13% of the total
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Annual review | The top ten explosive stocks in the US stock market for 2024 have been released! Applovin emerges as the dark horse of the year in AI, MSTR astonishes the market with a fivefold increase for the year, and Tesla makes a comeback in the last
As of the market close on December 11, the S&P 500 Index has risen by 27% year-to-date, surpassing 6,000 points; the Nasdaq Composite Index has accumulated a rise of over 33%, reaching a milestone of 0.02 million points, exceeding market expectations.
Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites
$1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today
10 BofA U.S. Options Overwriting Ideas
RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $84 Price Target
BofA Restarts Coverage of 11 Large-cap Biopharmas
10 Health Care Stocks With Whale Alerts In Today's Session
Incyte's Late-Breaking ASH 2024 Data Show Tafasitamab (Monjuvi) Significantly Improves Progression-Free Survival In Relapsed/Refractory Follicular Lymphoma, Meeting Phase 3 InMIND Trial Endpoints; U.S. SBLA Filing Planned By Year-End 2024
B of A Securities Reinstates Buy on Gilead Sciences, Announces $109 Price Target
Gilead Sciences Analyst Ratings
Gilead Company Kite Reports Results From Five-year Follow-up Analysis Of ZUMA-5, A Phase 2 Study Of Yescarta
Kite, A Gilead Company Presents Longest Follow-Up Data Reported For Tecartus CAR T-Cell Therapy At ASH 2024 Reinforce Durable Efficacy And Survival Benefits; ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, In...
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today